Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
2.340
0.00 (0.00%)
Nov 26, 2025, 4:00 PM EST - Market closed
Anebulo Pharmaceuticals Employees
As of June 30, 2025, Anebulo Pharmaceuticals had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,814,127
Market Cap
96.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3 | 0 | - |
| Jun 30, 2024 | 3 | 1 | 50.00% |
| Jun 30, 2023 | 2 | -2 | -50.00% |
| Jun 30, 2022 | 4 | 1 | 33.33% |
| Jun 30, 2021 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANEB News
- 14 days ago - Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates - Business Wire
- 2 months ago - Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates - Business Wire
- 2 months ago - Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity - Business Wire
- 2 months ago - Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives - Business Wire
- 4 months ago - Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock - Business Wire
- 7 months ago - Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates - Business Wire
- 10 months ago - Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates - Business Wire
- 1 year ago - Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise - Business Wire